New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Invenra Welcomes Three Industry Leaders to Its Board of Directors
-
DeltaStream Raises $15M in Series A Funding to Deliver the Future of Real-Time Stream Processing in Cloud
-
'AI godmother' Fei-Fei Li raises $230 million to launch AI startup
-
Habitat Health announces founding leadership team and more than $50 million in capital investments
-
HEAVY.AI Accelerates Big Data Analytics with Vultr's High-Performance GPU Cloud Infrastructure
-
On National Cellulite Day, New Omnibus Survey Results Reveal Cellulite Myths and Find Nearly 80% of Women with Cellulite on Their Buttocks and Thighs State Creams and Gadgets Don't Work Over the Long
-
CVRx (CVRX) Appoints Kevin Ballinger and Mitch Hill to its Board
-
CVRx Announces Appointment of Two New Board Members
-
Orby and Databricks Partner to Revolutionize Generative AI Automation for the Enterprise
-
Orby Expands Industry’s Leading Research, Machine Learning And Foundation Model Team
-
Moximed Completes Closing of Series D Financing for $91 Million to Accelerate Commercialization of MISHA® Knee System, an Implantable Shock Absorber for Knee Osteoarthritis
-
Form SC 13D/A Monte Rosa Therapeutics, Filed by: New Enterprise Associates 17, L.P.
-
MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism
-
Aligos Therapeutics Strengthens Board with Two New Independent Directors
-
Orby Launches ActIO the First Agentic AI Foundation Model to Set New Industry-Leading Performance Benchmarks
-
MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform
-
Clio announces US $900M investment at US $3B valuation to transform the legal experience for all
-
Brenig Therapeutics Announces $65 Million Series A Financing to Advance Leading Pre-Clinical Parkinson's Disease Pipeline
-
Magenta Medical Closes $105M Financing Led by Novo Holdings
-
Form 144 Tuya Inc./ADR Filed by: New Enterprise Associates 14, L.P.
-
Hivebrite takes Community Engagement to the Next Level with the Acquisition of AI-powered Matching Engine Orbiit
-
ASPIRE-FTD Phase 1/2 Clinical Trial Opens in the U.S. at The Ohio State University Wexner Medical Center
-
Orby AI Raises $30 Million to Deliver the First Large Action Model for AI Automation Unlocking Unrivaled Enterprise Efficiencies
-
MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer
-
TMRW Sports Completes Series A Investment Round, Co-led by Dynasty Equity and Connect Ventures
-
Decagon raises $35 million for AI-powered customer service
-
NEA Appoints Andrew Schoen and Blake Wu to Senior Investing Team Roles, Promotes Alex Sharata to Partner
-
PostgreSQL is Now Faster than Pinecone, 75% Cheaper, with New Open Source Extensions
-
Anterior Secures $20 Million Series A to Unlock Administrative Efficiencies for Healthcare Payers
-
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
-
Stride and Roadie Partner to Empower Drivers with Financial Tools
-
NODAR Transforms Automated Parking By Eliminating The Need For Ultrasonic Sensors And Providing Detailed 3D Surroundview Maps
-
Form SC 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A Marker Therapeutics, Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A BuzzFeed, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Form SC 13D/A BuzzFeed, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Form SC 13D/A SYNLOGIC, INC. Filed by: New Enterprise Associates 14, L.P.
-
Form SC 13D/A ZeroFox Holdings, Inc. Filed by: New Enterprise Associates 14, L.P.
-
Form SC 13D/A Monte Rosa Therapeutics, Filed by: New Enterprise Associates 17, L.P.
-
Form SC 13D/A Black Diamond Therapeuti Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A NEXTNAV INC. Filed by: New Enterprise Associates 14, L.P.
-
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
-
Form SC 13D/A GLYCOMIMETICS INC Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
Form SC 13D/A Reneo Pharmaceuticals, Filed by: New Enterprise Associates 15, L.P.
-
In-House Health Raises $4 Million Seed Round, Unveils AI-Powered Scheduling Platform to Combat Nurse Shortage Crisis
-
Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
-
Form SC 13D/A CHAMPIONS ONCOLOGY, INC. Filed by: New Enterprise Associates 14, L.P.
-
Form SC 13D/A Inventiva S.A. Filed by: New Enterprise Associates 17, L.P.
-
Form SC 13D/A Desktop Metal, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Form SC 13D/A RHYTHM PHARMACEUTICALS, Filed by: NEW ENTERPRISE ASSOCIATES 13 LP

